GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

HBI-2375   Click here for help

GtoPdb Ligand ID: 14178

Synonyms: formula IIIb [WO2023177592] | HBI2375 | HYBI-084
Compound class: Synthetic organic
Comment: HBI-2375 acts as an inhibitor of the protein-protein interaction between MLL1 and WDR5 [1]. This is a molecular mechanism that is proposed for the elimination of cancer stem cells in certain tumours. It is brain-penetrant, but lacks potency in functional studies using leukemia cells (GI50 > 3μM). HBI-2375 is identified as HBI-2375/HYBI-084 in patent WO2023177592A1 [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 11
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 113.11
Molecular weight 616.11
XLogP 1.51
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C[C@H]1CN(C[C@@H](C)N1C)C2=CC(=C(C=C2NC(=O)C3=C(C(=C(C(=C3)N)F)C)Cl)N4C=C(C(=O)N5CCN(C)CC5)N=N4)F
Isomeric SMILES C[C@H]1CN(C[C@@H](C)N1C)C2=CC(F)=C(C=C2NC(=O)C3=C(Cl)C(C)=C(F)C(N)=C3)N4C=C(N=N4)C(=O)N5CCN(C)CC5
InChI InChI=1S/C29H36ClF2N9O2/c1-16-13-40(14-17(2)38(16)5)25-11-20(31)24(41-15-23(35-36-41)29(43)39-8-6-37(4)7-9-39)12-22(25)34-28(42)19-10-21(33)27(32)18(3)26(19)30/h10-12,15-17H,6-9,13-14,33H2,1-5H3,(H,34,42)/t16-,17+
InChI Key ZAAAXOTWIKLEGP-CALCHBBNSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Coker JA, Martinez SR, Han SH, Sloan AR, Gupta AK, Bukenya G, Polzer P, Ramos JH, Rico E, Rico A et al.. (2025)
Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of Glioblastoma.
biorxiv, Preprint. DOI: 10.1101/2025.07.29.667410
2. Shojaei F, Fang C, Semple E, Gillings M. (2023)
Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof.
Patent number: WO2023177592A1. Assignee: Huyabio International, Llc. Priority date: 10/03/2023. Publication date: 21/09/2023.